Recommendation of the President – Ebglyss (lebrikizumab)

On 26 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 21/2025 on the appraisal Ebglyss (lebrikizumab) as part of the drug program “Treatment of patients with atopic dermatitis (ICD-10: L20)”

Publication in Public Information Bulletin (BIP) >>